학술논문

Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab
Document Type
Article
Source
Ophthalmic Plastic and Reconstructive Surgery; March-April 2023, Vol. 39 Issue: 2 p150-155, 6p
Subject
Language
ISSN
07409303; 15372677
Abstract
Despite a national teprotumumab shortage resulting from COVID-19 pandemic, patients who were partially treated with teprotumumab achieve significant reduction in proptosis, clinical activity score, and extraocular muscle restriction and maintain these improvements during short-term interruption.